490 related articles for article (PubMed ID: 30616029)
1. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
[TBL] [Abstract][Full Text] [Related]
3. Intravenous bisphosphonate therapy in children with spinal muscular atrophy.
Nasomyont N; Hornung LN; Wasserman H
Osteoporos Int; 2020 May; 31(5):995-1000. PubMed ID: 31788718
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
6. Incidence of serious side effects with intravenous bisphosphonate: a clinical audit.
Powell D; Bowler C; Roberts T; Garton M; Matthews C; McCall I; Davie M
QJM; 2012 Oct; 105(10):965-71. PubMed ID: 22753670
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
[TBL] [Abstract][Full Text] [Related]
8. Treatment for osteoporosis in people with ß-thalassaemia.
Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
12. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD002010. PubMed ID: 24627308
[TBL] [Abstract][Full Text] [Related]
14. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
15. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
